| Literature DB >> 30868536 |
Uriel Ortega-Rodriguez1, Susana Portillo1, Roger A Ashmus2, Jerry A Duran1, Nathaniel S Schocker2, Eva Iniguez1, Alba L Montoya2, Brenda G Zepeda1, Janet J Olivas1, Nasim H Karimi1, Julio Alonso-Padilla3, Luis Izquierdo4, Maria-Jesús Pinazo4, Belkisyolé Alarcón de Noya5, Oscar Noya5, Rosa A Maldonado1, Faustino Torrico6,7, Joaquim Gascon5, Katja Michael2, Igor C Almeida8.
Abstract
Chagas disease (ChD), caused by the protozoan parasite Trypanosoma cruzi, affects millions of people worldwide. Chemotherapy is restricted to two drugs, which are partially effective and may cause severe side effects, leading to cessation of treatment in a significant number of patients. Currently, there are no biomarkers to assess therapeutic efficacy of these drugs in the chronic stage. Moreover, no preventive or therapeutic vaccines are available. In this chapter, we describe the purification of Trypanosoma cruzi trypomastigote-derived glycosylphosphatidylinositol (GPI)-anchored mucins (tGPI-mucins) for their use as antigens for the reliable primary or confirmatory diagnosis and as prognostic biomarkers for early assessment of cure following ChD chemotherapy. We also describe, as an example, the synthesis of a potential tGPI-mucin-derived α-Gal-terminating glycan and its coupling to a carrier protein for use as diagnostic and prognostic biomarker in ChD.Entities:
Keywords: Anti-α-Gal antibodies; Biomarkers; Carbohydrate synthesis; Chagas disease; Chemiluminescent enzyme-linked immunosorbent assay; Chemotherapy; Diagnosis; Mucins; Neoglycoproteins; Trypanosoma cruzi
Mesh：
Substances：
Year: 2019 PMID： 30868536 PMCID： PMC6589430 DOI： 10.1007/978-1-4939-9148-8_22
Source DB: PubMed Journal: Methods Mol Biol ISSN： 1064-3745